MCC-950

CAT: 0400-SIH-604-25MGSize: 25 mgDry Ice: NoHazardous: No
CAT#: SIH-604-25MGSize: 25 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1Product image 2
1 / 2
Background
NLRP3 (MCC950) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1(1). Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes(2). Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations3. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model)(3). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome(4). A valuable new tool for exploring the pathophysiology of NLRP3. It may contribute to additional alpha synuclein aggregation and cell loss in PD (5).
Description
NLRP3 inflammasome activation inhibitor
CAS Number
256373-96-3
Product Name Alternative
N-[[ (1,2,3,5,6,7-Hexahydro-s-indacen-4-yl) amino]carbonyl]-4- (1-hydroxy-1-methylethyl) -2-furansulfonamide sodium salt; CRID3; CP-456773 sodium salt
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cell Signaling | Growth Factors | TNF | Neuroscience | Neurodegeneration | Parkinson's Disease | Synuclein| Cancer
Purity
>98% (HPLC) ; NMR (Conforms)
Weight
0.005
Format
White powder
Solubility
May be dissolved in water (30 mg/ml): or DMSO (40 mg/ml)
Molecular Formula
C20H23N2O5S ∙ Na
Molecular Weight
426.5
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Laliberte R.E. et al. (2003) J. Biol. Chem. 278(19):16567-78. 2. Coll R.C., et al. (2011) PLoS One. 6(12):e29539. 3. Coll R.C., et al. (2015) Nat. Med. 21(3):248-255. 4. Kaneko N., et al. (2015) J. Immunol. Methods. 426:76-81. 5. Nguyen L., et al. (2022) J Parkinsons Dis. 12(7): 2117-2133.

Related Products

CatalogName